Technical Data

C2382-13X-ML490
Clone Type
Monoclonal
Host
Mouse
Source
Human
Conjugate
MaxLight™490
Isotype
IgG1
Clone Number
HRS4
Grade
Affinity Purified
Applications
IHC
Crossreactivity
Hu
Shipping Temp
Blue Ice
Storage Temp
4°C Do Not Freeze
Notes
Preservative Free
BSA Free
Mouse Anti-CD30 (CD30L Receptor, D1S166E, Ki1 Antigen, Lymphocyte Activation Antigen CD30, Tumor Necrosis Factor Receptor Superfamily Member 8 Precursor, Hodgkin & Reed-Sternberg Cell Marker, TNFRSF8) (BSA & Azide Free) (MaxLight 490)

CD30, a single chain glycoprotein, is synthesized as a 90kD precursor which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kD glycoprotein. The CD30/Ki-1 antigen is expressed by mononuclear Hodgkin and multinucleated Reed-Sternberg cells in Hodgkin’s disease, by the tumor cells of a majority of anaplastic large cell lymphomas, and by a varying proportion of activated T and B cells. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45). MW of Antigen: 120kD (mature), 95kD (precursor)

Applications
Suitable for use in Immunohistochemistry (paraffin). Other applications have not been tested.
Recommended Dilution
Immunohistochemistry (frozen and formalin/paraffin): 1:40-1:80. Staining of formalin-fixed tissues requires boiling tissue sections in 1mM EDTA, pH 8.0, for 10-20 min followed by cooling at RT for 20 min. Note that 1mM EDTA, pH 8.0 is better than 10mM citrate buffer, pH 6.0 for unmasking the epitope.
Optimal dilutions to be determined by the researcher.
Positive Control: Hodgkin’s lymphoma
Cellular Localization: Cell membrane
Storage and Stability
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (40-50%). Freeze at-20°C or colder. Aliquots are stable for at least 12 months at-20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Note: Applications are based on unconjugated antibody.
Immunogen
Recombinant protein corresponding to the extracellular domain of human CD30. Cellular Localization: Cell membrane
Form
Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with MaxLight™490.
Purity
Purified by Protein G affinity chromatography.
Specificity
Recognizes human CD30 (Reed-Sternberg Cell Marker).

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

References
1. Schwarting R, et. al. Blood, 1989, 74(5):1678- 89. 2. Battelli MG, et al. Virchows Archiv, 1996 Feb, 427(5):529–35. 2. Bolognesi A, et ak, International Journal of Cancer, 1996 Nov 4, 68(3):349–55. 3. Hittmair A, et al. Human Pathology, 1996 Nov, 27(11):1166–71. 4. Terenzi A, et al. British Journal of Haematology, 1996 Mar, 92(4):872–9. 5. Zakowski MF, et al. Diagnostic Cytopathology, 1996 Mar, 14(2):155–61. 6. Bolognesi A, et al. Cancer Immunology, Immunotherapy, 1995 Feb, 40(2):109–14. 7. Fraga M, et al. American Journal of Clinical Pathology, 1995 Jan, 103(1):82–9. 8. Horn-Lohrens O, et al. International Journal of Cancer, 1995 Feb 8, 60(4):539–44. 9. Latza U, et al. American Journal of Pathology, 1995 Feb, 146(2):463–71. 10. Pasqualucci L, et al. Blood, 1995 Apr 15, 85(8):2139–46. 11. Sass U, et al. Dermatology, 1995, 190(4):327–9. 12. Tian ZG, et al. Cancer Research, 1995 Nov 15, 55(22):5335–41. 13. Zarate-Osorno A, et al. Cancer, 1995 Mar 15, 75(6):1360–6. 14. Battelli MG, et al. Hepatology, 1994 Oct, 20(4 Pt 1):940–7. 15. el-Azhary RA, et al. Journal of the American Academy of Dermatology, 1994 Feb, 30(2 Pt 1):210–8. 16. Ferreiro JA, et al. Human Pathology, 1994 May, 25(5):522–4. 17. Ito K, et al. American Journal of Pathology, 1994 Aug, 145(2):276–80. 18. Oka K, et al. Dermatology, 1994, 188(1):52–6. 19. Schwend M, et al. European Respiratory Journal, 1994 Mar, 7(3):612–6. 20. Cambiaggi A, et al. British Journal of Haematology, 1993 Oct, 85(2):270–6. 21. Charalambous C, et al. Journal of Clinical Pathology, 1993 Dec, 46(12):1085–8. 22. Enblad G, et al. Histopathology, 1993 Jun, 22(6):535–41. 23. Gordon BG, et al. Cancer, 1993 Jan 1, 71(1):257–63. 24. Krishnan J, et al. Journal of Cutaneous Pathology, 1993 Jun, 20(3):193–202. 25. Parente A, et al. Biochim Biophys Acta, 1993 Oct 19, 1216(1):43–9. 26. Tallini G, et al. Journal of Clinical Gastroenterology, 1993 Jul, 17(1):57–66. 27. Vanbockrijck M, et al. Cancer, 1993 Sep 1, 72(5):1784–9. 28. Durkop H, et al. Cell, 1992 Feb 7, 68(3):421–7. 29. Falini B, et al. Lancet, 1992 May 16, 339(8803):1195- 6. 30. Falini B, et al. British Journal of Haematology, 1992 Sep, 82(1):38–45. 31. Kanzaki T, et al. Cancer, 1992 Feb 15, 69(4):1034–41. 32. Miyazono M, et al. Acta Neuropathologica, 1992, 84(5):577- 80. 33. Perkins PL, et al. Archives of Pathology and Laboratory Medicine, 1992 Nov, 116(11):1192–6. 34. Sarker AB, et al. American Journal of Pathology, 1992 Jul, 141(1):19–23.
USBio References
No references available
United States Biological | 4 Technology Way | Salem, MA 01970
Phone 800-520-3011 | Fax 978-594-8052 | Website www.usbio.net